XML 39 R26.htm IDEA: XBRL DOCUMENT
v3.23.1

Collaboration and License Agreements and Supply Agreements (Tables) | 3 Months Ended
--- | ---
Mar. 31, 2023
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Summary of Recognized Revenue | In accordance with the collaboration agreements, the Company recognized revenue as follows:
|  | Three Months Ended |
|  | March 31, |
|  | 2023 |  |  | 2022 |
|  | (in thousands) |
Bristol Myers Squibb Company (“BMS”) |  | $ | 3,166 |  |  | $ | 2,165 |
Merck Sharp & Dohme Corporation (“Merck”) |  |  | 2,553 |  |  |  | 1,064 |
Merck KGaA, Darmstadt, Germany (operating in the United States and Canada under the name “EMD Serono”) |  |  | 8 |  |  |  | 1,897 |
Astellas Pharma Inc. (“Astellas”) |  |  | 6,272 |  |  |  | - |
Vaxcyte |  |  | 675 |  |  |  | 771 |
Total revenue |  | $ | 12,674 |  |  | $ | 5,897 |
Summary of Deferred Revenue Balance | The following table presents the changes in the Company’s deferred revenue balance from collaboration agreements during the three months ended March 31, 2023:
|  | Three Months Ended |
|  | March 31, 2023 |
|  | (in thousands) |
Deferred revenue—December 31, 2022 |  | $ | 106,644 |
Additions to deferred revenue |  |  | 1,018 |
Recognition of revenue in current period |  |  | (5,430 | )
Deferred revenue—March 31, 2023 |  | $ | 102,232 |
2018 BMS Master Services Agreement |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Summary of Recognized Revenue | Revenues under the BMS Agreement and the 2018 BMS Master Services Agreement were as follows:
|  | Three Months Ended |
|  | March 31, |
|  | 2023 |  |  | 2022 |
|  | (in thousands) |
Research and development services |  | $ | 221 |  |  | $ | 244 |
Materials supply |  |  | 2,945 |  |  |  | 1,921 |
Total revenue |  | $ | 3,166 |  |  | $ | 2,165 |
2020 Merck Master Services Agreement |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Summary of Recognized Revenue | Revenues under the 2018 Merck Agreement and the 2020 Merck Master Services Agreement were as follows:
|  | Three Months Ended |
|  | March 31, |
|  | 2023 |  |  | 2022 |
|  | (in thousands) |
Ongoing performance related to unsatisfied performance obligations |  | $ | - |  |  | $ | 862 |
Research and development services |  |  | 125 |  |  |  | 173 |
Materials supply |  |  | 2,428 |  |  |  | 29 |
Total revenue |  | $ | 2,553 |  |  | $ | 1,064 |
2019 EMD Serono Supply Agreement |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Summary of Recognized Revenue | Revenues under the EMD Serono agreements were as follows:
|  | Three Months Ended |
|  | March 31, |
|  | 2023 |  |  | 2022 |
|  | (in thousands) |
Research and development services |  | $ | 6 |  |  | $ | 284 |
Materials supply |  |  | 2 |  |  |  | 1,613 |
Total revenue |  | $ | 8 |  |  | $ | 1,897 |
Supply Agreement | Vaxcyte, Inc. |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Summary of Recognized Revenue | Revenues under the Vaxcyte Supply Agreement were as follows:
|  | Three Months Ended |
|  | March 31, |
|  | 2023 |  |  | 2022 |
|  | (in thousands) |
Research and development services |  | $ | 504 |  |  | $ | 601 |
Materials supply |  |  | 171 |  |  |  | 170 |
Total revenue |  | $ | 675 |  |  | $ | 771 |
Astellas License and Collaboration Agreement |
Collaborative Arrangements And Noncollaborative Arrangement Transactions [Line Items] |
Summary of Recognized Revenue | Revenues under the Astellas Agreement were as follows:
|  | Three Months Ended |
|  | March 31, |
|  | 2023 |  |  | 2022 |
|  | (in thousands) |
Ongoing performance related to unsatisfied performance obligations |  | $ | 2,572 |  |  | $ | - |
Research and development services |  |  | 1,157 |  |  |  | - |
Financing component on unearned revenue |  |  | 2,543 |  |  |  | - |
Total revenue |  | $ | 6,272 |  |  | $ | - |

X
- Definition Milestone method revenue recognition. + References No definition available. + Details
Name: | stro_MilestoneMethodRevenueRecognitionTableTextBlock
Namespace Prefix: | stro_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Definition Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table. + References No definition available. + Details
Name: | us-gaap_CollaborativeArrangementsAndNoncollaborativeArrangementTransactionsLineItems
Namespace Prefix: | us-gaap_
Data Type: | xbrli:stringItemType
Balance Type: | na
Period Type: | duration

X
- Definition Tabular disclosure of the type of arrangements and the corresponding amounts that comprise the current and noncurrent balance of deferred revenue as of the balance sheet date. + References No definition available. + Details
Name: | us-gaap_DeferredRevenueByArrangementDisclosureTextBlock
Namespace Prefix: | us-gaap_
Data Type: | dtr-types:textBlockItemType
Balance Type: | na
Period Type: | duration

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_TwoThousandEighteenBmsMasterServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_TwoThousandTwentyMerckMasterServicesAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_TwoThousandNineteenEMDSeronoSupplyAgreementsMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_SupplyAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | srt_CounterpartyNameAxis=stro_VaxcyteIncMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |

X
- Details
Name: | us-gaap_TypeOfArrangementAxis=stro_AstellasLicenseAndCollaborationAgreementMember
Namespace Prefix: |
Data Type: | na
Balance Type: |
Period Type: |